IMIQUIMOD 5 %
IMIQUIMOD : 5 % · DIN 02413582 · BAUSCH HEALTH, CANADA INC.
Health Canada status: APPROVED
What is IMIQUIMOD?
IMIQUIMOD 5 % contains IMIQUIMOD : 5 %. It is listed in the Health Canada Drug Product Database under DIN 02413582, held by BAUSCH HEALTH, CANADA INC., supplied as CREAM for TOPICAL administration. Health Canada currently lists it as approved, status dated 03-Mar-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IMIQUIMOD used for?
Treatment of primary superficial basal cell carcinoma (sBCC), nonhyperkeratotic actinic keratosis (AK) on face/scalp, and external genital/perianal warts in immunocompetent adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02413582 |
|---|---|
| Brand name | IMIQUIMOD |
| Generic / active ingredient | IMIQUIMOD : 5 % |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 5 % |
| Dosage form | CREAM |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D06BB10 IMIQUIMOD |
| AHFS class | 84:04.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 03-Mar-2021 |
| Original market date | 2014-07-01 00:00:00 |
How is it administered?
Apply topically. sBCC: 5x/week for 6 weeks. AK: 2x/week for 16 weeks. External genital warts: 3x/week until clearance (max 16 weeks). Wash area with mild soap/water before and 6-10 hours after.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text.
How is it supplied?
Not explicitly detailed in provided text (typically supplied in single-use packets).
Contraindications
Contraindicated in individuals with a history of sensitivity reactions to any of its components. Discontinue if hypersensitivity is noted.
Warnings and precautions
Regular follow-up required for sBCC. Not for other BCC types. Avoid/minimize sunlight/UV exposure. May cause permanent skin color changes. Discontinue if hypersensitivity or erythema multiforme occur.
What can be used instead?
Other Canadian products sharing ATC code D06BB10 IMIQUIMOD. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALDARA P | 5 % | CREAM | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02239505 |
| TARO-IMIQUIMOD PUMP | 5 % | CREAM | TARO PHARMACEUTICALS INC | MARKETED | DIN 02482983 |
| VYLOMA | 3.75 % | CREAM | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02365561 |
| ZYCLARA | 3.75 % | CREAM | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02340445 |
| APO-IMIQUIMOD | 5 % | CREAM | APOTEX INC | DORMANT | DIN 02407825 |
| TARO-IMIQUIMOD | 5 % | CREAM | TARO PHARMACEUTICALS INC | APPROVED | DIN 02482975 |
| ZYCLARA | 2.5 % | CREAM | BAUSCH HEALTH, CANADA INC. | APPROVED | DIN 02392054 |
Who else supplies IMIQUIMOD worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IMIQUIMOD appears in 42 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.